Trastuzumab for early breast cancer: evolution or revolution?
Littlejohns
Peter
P
UK National Institute for Health and Clinical Excellence, London. Peter.littlejohns@nice.org.uk
D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D035843:Biomedical Research; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006801:Humans; D009313:National Health Programs; D009367:Neoplasm Staging; D012109:Research Support as Topic; D016019:Survival Analysis; D000068878:Trastuzumab; D006113:United Kingdom
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab